Collplant Biotechnologies LTCLGN
13F holders, Q4 2025 (December 31)16holders −2
3new positions
4sold out
1famous investor
$1.40avg. 13F price*
At the end of Q4 2025, 16 institutions reported holding Collplant Biotechnologies LT (CLGN) in their 13F filings, down 2 from Q3 2025. 3 opened new positions and 4 sold out. The largest holders were Villere St Denis J & Co. LLC ($850K), Pinnacle Associates Ltd. ($780K) and Brown Advisory Inc. ($166K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Collplant Biotechnologies LT
- CUSIP
- M2R51X116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $42K |
| Exits | 4 | $53K |
All 13F filers, Q3 2025 → Q4 2025: 98,242 shares bought and 34,688 shares sold, net +63,554 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Villere St Denis J & Co. LLC | 0.09% | Add +3.2% | 607,300 | $850K |
| Pinnacle Associates Ltd. | 0.01% | Add +9.9% | 557,193 | $780K |
| Brown Advisory Inc. | 0.00% | No change | 118,731 | $166K |
| Renaissance Technologies | 0.00% | Reduce -19.6% | 17,600 | $25K |
| Pathstone Holdings, LLC | 0.00% | No change | 17,000 | $24K |
| XTX Topco Ltd | 0.00% | New | 14,381 | $20K |
| Waters Parkerson & Co., LLC | 0.00% | No change | 13,250 | $19K |
| Virtu Financial LLC | 0.00% | New | 11,806 | $17K |
| FNY Investment Advisers, LLC | 0.00% | No change | 5,250 | $7K |
| Group One Trading LLC | 0.00% | Reduce -2.0% | 4,900 | $7K |
| Legacy Wealth Managment, LLC | 0.00% | New | 3,472 | $5K |
| Bank of America Corp. | 0.00% | No change | 2,500 | $4K |
| Wells Fargo & Company | 0.00% | Reduce -80.0% | 2,000 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 335 | $469 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -0.5% | 200 | $280 |
| Morgan Stanley | 0.00% | Reduce -100.0% | 1 | $3 |
"% of holder's portfolio" is CLGN's weight in each manager's 13F, not the share of Collplant Biotechnologies LT the manager owns.